Gregory T. Lucier has demonstrated a clear buying bias in recent insider transactions, with $2.07 million in total purchases compared to $915,708 in sales across three companies—DENTSPLY SIRONA (XRAY), Avantor (AVTR), and Maravai LifeSciences (MRVI). His most significant activity has centered on XRAY, where he executed multiple purchases in early 2026, including a $392,520 acquisition on March 2 and a $314,858 transaction the following day. This follows a December 2025 sale of $915,708 in XRAY shares, his only recent disposition. Prior to that, Lucier had been accumulating positions in MRVI, with purchases of $190,446 and $178,097 in December 2025, and made a substantial $458,000 investment in AVTR in February 2026. The pattern shows a shift from earlier activity—where most filings involved grants or awards (coded "A" or "G") with zero reported value—to recent, high-value open market purchases (coded "P"). While his role at these companies isn't specified in the filings, the transactional data reveals a concentrated buildup in healthcare-related stocks, particularly XRAY, with recent purchases outpacing sales by an 8-to-1 ratio since late 2025.
AI-assisted summary